C22H30O4 · MW ≈ 358.47 · CAS 185505-15-1 · non-intoxicating raw acid · acid precursor of CBC · the third CBGA branch (via CBCA synthase) · decarboxylates to CBC (~110–160 °C)
40 questions are answered here. 23 carry a verified grade on the six-rung evidence ladder. 13 are marked with an evidence state rather than a rung — most often no primary evidence, which means our registry holds nothing on that question. That is not the same claim as not supported, and we do not render it as one. The remaining 4 carry an author qualifier that is not yet part of the controlled vocabulary, so they are shown without a grade chip rather than with a guessed one — catalogue in progress.
Verified science — what CBCA *is*, its formula/CAS, how it forms from CBGA, that it decarboxylates to CBC, and that the raw acid is non-intoxicating — is stated as fact with a grade. Any effect or benefit is **reported as a third-party claim** and paired with the honest limit; **CBG Atlas does not make, adopt, or affirm these claims**. Where evidence is thin we say "catalogue in progress." Not medical or legal advice.
CBCA (cannabichromenic acid) is the raw, non-intoxicating acid precursor of CBC (cannabichromene). The plant makes CBCA from CBGA, and heating decarboxylates CBCA to CBC. That chemistry is Established. CBCA's own effects in people are a separate matter: no controlled human study of CBCA has been published, so this is untested rather than tested-and-null, and we mark everything past the chemistry catalogue in progress.
CBCA stands for cannabichromenic acid — the carboxylic-acid ("-ic acid") precursor of cannabichromene (CBC). The "A" marks the acid group the living plant makes first, before heat converts CBCA to CBC. Its formula is C22H30O4, molecular weight ≈ 358.47, CAS 185505-15-1. The name describes chemistry, and that chemistry is Established; the name implies nothing about an effect.
CBCA is one of the three branches from the "mother acid" CBGA: a synthase enzyme (CBCA synthase) converts CBGA into CBCA, alongside the THCA and CBDA branches. Notably, the THCA/CBDA synthases aren't perfectly specific and also yield some CBCA (Zirpel 2018, PMID 30053500).
Yes — CBCA is a naturally occurring cannabinoid acid, made by the cannabis plant from CBGA. CBCA is the raw form present before heating; the neutral CBC appears mainly after heat, drying, or aging drives off CO₂ from CBCA. CBCA can also be prepared as a laboratory reference standard, but the molecule in hemp is plant-made. Established plant chemistry.
No. As a raw cannabinoid acid, CBCA is non-intoxicating — cannabinoid acids don't activate the CB1 receptor the way THC does. Its heated product, CBC, is also non-intoxicating. There is no verified evidence that CBCA produces any high in people.
No — CBCA is not known to be intoxicating, and its heated form CBC is non-intoxicating too. Whether the raw acid has any subtle psychoactive effect is genuinely unstudied rather than studied-and-ruled-out: no controlled human data on CBCA exist in either direction. That half of the question is catalogue in progress, and we would rather say so than guess.
CBCA's effects in the body are not established. The one verified in-vitro handle for cannabinoid acids as a class is inhibition of the enzyme DAGLα (De Petrocellis 2011, PMID 21175579) — a cell-level finding, not a human effect. Catalogue in progress.
Unheated, CBCA is a non-intoxicating acid whose specific activity in people is unverified. Some "raw cannabinoid" interest exists, but CBCA's raw effects are not established (not medical advice). To obtain neutral CBC, the acid must be decarboxylated with heat. Catalogue in progress.
Legality depends on source and jurisdiction, not the molecule alone. Where hemp-derived cannabinoids under 0.3% Δ⁹-THC are permitted, CBCA generally falls in that framework; elsewhere it may be restricted. This is a general, dated snapshot (2026-07-11), not legal advice — verify locally.
Generally yes, with one important limit. In the US, hemp-derived CBCA in a product at or below 0.3% Δ⁹-THC by dry weight is generally federally legal as a hemp product under the 2018 Farm Bill — but the FDA has not authorised cannabinoids as foods or dietary supplements, so a lawful hemp derivative is not automatically a lawful food ingredient. Dated 2026-07-11; general information, not legal advice.
CBCA's status depends on your state, and we cannot determine that for you here. US state laws vary, and some restrict hemp cannabinoids more tightly than federal law. CBCA is essentially never named specifically in statute, so it usually inherits your state's general hemp and THC rules. Check your state's current statute, or ask a qualified attorney. Dated 2026-07-11; informational only, not legal advice.
Generally no — not as a food or supplement you can freely sell. The EU and UK classify extracted cannabinoids as novel foods requiring authorisation, and CBCA is not specifically authorised; Canada regulates isolated phytocannabinoids under the Cannabis Act. Rules differ by product class and change often, so verify the current national position before relying on this. Dated 2026-07-11; general information, not legal advice.
None are established. CBCA has no verified human or preclinical evidence for any benefit. It is sometimes marketed within raw or full-spectrum products, but such claims are unproven and not affirmed by CBG Atlas (not medical advice). Catalogue in progress.
CBCA is used mainly as a raw-cannabinoid or full-spectrum ingredient and as a research/reference compound; it has no established therapeutic use. Its main practical role is biochemical — the acid precursor that becomes CBC when heated (not medical advice). Catalogue in progress.
Not established for CBCA. Some cannabinoids have shown antibacterial activity in lab studies, but that does not verify CBCA specifically, and no such claim is proven for it in people or animals (not medical advice). We report the claim; we don't affirm it. Catalogue in progress.
No — CBCA has never been tested in a controlled human trial. That is an absence of testing, not a test that came back negative: nobody has run the study, so nothing has been found for or against CBCA in a person. Verified data on CBCA stop at cell-level observations of cannabinoid acids, which is why CBG Atlas marks it catalogue in progress rather than claiming an effect.
CBCA's safety is not established — there are no human safety studies of CBCA, no defined dose, and no long-term data. Untested is the honest word: nobody has looked, so this is an open question rather than a clean bill of health, and non-intoxicating does not mean proven safe. Consult a qualified professional before use, especially alongside other medications. Catalogue in progress. (Not medical advice.)
CBCA's side-effect profile is unknown; no controlled studies document its adverse effects, and absence of data isn't evidence of safety. Products may contain other cannabinoids or contaminants. Stop use and seek advice if you feel unwell (not medical advice). Catalogue in progress.
No safe or effective CBCA dose has been established, so "too much" can't be defined from evidence, and no overdose data exist. As with any unstudied compound, more is not better. This is not dosing or medical advice. Catalogue in progress.
Nobody knows, because no interaction study of CBCA exists in people or in the laboratory — the question is untested rather than answered. Cannabinoids as a class can affect drug-metabolising enzymes, so an interaction is plausible for CBCA but entirely unverified, and plausible is not demonstrated. If you take any medication, consult a clinician or pharmacist before use. Catalogue in progress. (Not medical advice.)
Probably not. Standard drug tests screen for THC's metabolite (THC-COOH), not CBCA, and CBCA does not convert to THC, so direct interference is unlikely. The real variable is any trace THC in a hemp product. CBCA-specific cross-reactivity data are limited, so a current third-party certificate of analysis is the only way to see what a product actually contains.
No. CBCA is not THC and does not decarboxylate into THC — heating CBCA yields non-intoxicating CBC, and pure CBCA contains no THC at all. That much is Established chemistry. The product is the variable: hemp-derived goods can carry trace Δ⁹-THC unless made from isolate, so read the batch certificate of analysis (COA) rather than the front label.
CBCA is not what drug tests detect and doesn't form THC, so it is unlikely to be the direct cause of a failed test. The real risk is trace THC in a hemp product. If drug-tested, choose products with a COA showing non-detectable THC.
CBCA appears mostly in raw or full-spectrum hemp preparations and as a reference isolate, since heating converts it to CBC. It may be used sublingually or within a raw-cannabinoid blend. These are format notes only — CBCA has no studied route or dose (not medical advice).
CBCA is rare; products are limited to some raw or full-spectrum extracts and reference isolates for labs. Standalone consumer CBCA products are uncommon, and heating any product converts CBCA to CBC. Potency and purity vary, so a third-party certificate of analysis (COA) matters.
There is no established dose for CBCA. No clinical studies define a safe or effective amount, so CBG Atlas gives no dosing guidance. Any label amount reflects manufacturer choice, not evidence. Consult a qualified professional (not medical or dosing advice). Catalogue in progress.
To become CBC, yes — CBCA must be heated (decarboxylated) to drive off CO₂, roughly in the 110–160 °C range. Kept raw, it stays a non-intoxicating acid whose own effects are unstudied. Whether you want the acid or neutral form depends on the product.
CBCA is the raw plant acid; CBC is its heated, decarboxylated (neutral) form. Both are non-intoxicating. They differ by a single carboxyl group, lost as CO₂ when CBCA is heated. CBC is somewhat more discussed, but both are thin on verified human evidence.
CBGA is the "mother acid" that sits upstream; CBCA is one of its three branch products (via CBCA synthase), alongside THCA and CBDA. So CBGA precedes CBCA in biosynthesis. Both are non-intoxicating pentyl-series acids that decarboxylate to their neutral forms.
CBCA is the chromene-branch acid (→CBC), sibling to THCA (→THC) and CBDA (→CBD) on the pentyl line, all derived from CBGA. The varin acids (THCVA/CBDVA/CBGVA) are their propyl counterparts. All are non-intoxicating in raw form and decarboxylate to neutrals with heat.
"Raw" means the acid CBCA is intact and non-intoxicating; "decarbed" means heat has removed its carboxyl group and left neutral CBC. CBCA and CBC are chemically distinct molecules, and only decarbed material is CBC — an Established relationship. Neither one is an approved or established treatment for anything, and the human evidence for either is catalogue in progress. (Not medical advice.)
CBCA's molecular formula is C22H30O4 (molecular weight ≈ 358.47 g/mol), CAS 185505-15-1. Structurally, CBCA is the carboxylic-acid precursor of CBC (C21H30O2) and a direct branch product of CBGA, carrying a carboxyl group that neutral CBC lacks. Heating removes that group as CO₂ to give CBC. This chemical identity is Established; CBCA's biological effects are a separate, largely unstudied question.
CBCA is obtained from raw, unheated cannabis using gentle, heat-avoiding extraction — heat converts CBCA to CBC — followed by chromatographic purification. Because heat destroys the acid and CBCA is usually a minor plant component, isolating stable CBCA is low-yield and technically demanding, which is much of why finished CBCA products are rare. The extraction chemistry itself is Established.
Yes. CBCA is one of the three CBGA branches — CBCA synthase converts CBGA into CBCA, alongside THCA and CBDA. The THCA/CBDA synthases are also imperfectly specific and yield some CBCA from CBGA (Zirpel 2018). It is a verified branch of the biosynthetic tree.
CBCA decarboxylates to CBC with heat over time, roughly in the 110–160 °C window like other cannabinoid acids — gentler heat is slower and cleaner, hotter is faster but risks degradation. CBCA-specific decarboxylation kinetics are less published (catalogue in progress).
CBCA is sold by a small number of specialty hemp/cannabinoid and reference-chemical suppliers, usually as raw extracts or reference isolates. It is niche and inconsistently stocked. CBG Atlas endorses no specific brand — buy only from vendors that publish third-party lab results.
CBCA is typically a minor plant component, and it converts to CBC with almost any heat, so isolating stable CBCA is low-yield and technically demanding. Cold handling, cold storage, and extra purification all add cost. Limited supply plus specialised handling is what makes CBCA rare and expensive next to abundant cannabinoids like CBD — scarcity is a supply fact, not a sign of potency.
Request a current certificate of analysis (COA) from an accredited third-party lab confirming CBCA content, showing the THC level, and screening for pesticides, solvents, and heavy metals. The label should match the COA. No COA, or a mismatched one, is a red flag.
That is your call, and the honest input is this: CBCA has no established benefit and has never been tested in a controlled human trial, so any value is speculative rather than evidence-based — untested, not tested-and-rejected. Catalogue in progress. If you do try it, prioritise lab-tested products with a current certificate of analysis and keep expectations proportionate to the evidence. (Not medical advice.)
Look for a third-party COA matching the label, compliant and clearly declared THC, stated cannabinoid amounts, contaminant screening, and transparent sourcing. Be sceptical of any health claim attached to CBCA: none is verified, and CBCA's evidence file is catalogue in progress rather than positive. Testing and transparency are the only things you can actually check at the point of purchase. (Not medical advice.)
CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Statements about effects, benefits or uses reflect claims made by third parties — CBG Atlas does not make, adopt or affirm them. Legal status is scoped to jurisdiction, product class and date, and moves; verify against the official source. See how we grade and the safety page. Peregrine Biopharma funds the platform and holds no editorial authority.